Search Medical Condition
Please enter condition
Please choose location from dropdown

Nantes cedex 1, France Clinical Trials

A listing of Nantes cedex 1, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (506) clinical trials

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

The study consists of 5 cohorts: Cohort 1 (Single-Agent Dose-Finding) will use dose-escalation to find the recommended dose (RD) of lenvatinib using a time-to-event continual reassessment method (TiTE-CRM) design in children and adolescents with relapsed or refractory solid malignant tumors. When the RD is identified, Cohorts 2A, 2B, and 3A ...

Phase

0.0 miles

Learn More »

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment {ME2} Cohort). Participants may also receive ...

Phase

0.0 miles

Learn More »

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

Delayed immune-reconstitution remains one of the main limitation of haploidentical stem cell transplantation. The risk of severe infections remains high for several months and CD3+ reconstitution could take more than 10 months. The low number of lymphocytes infused with the graft, the degree of HLA (Human Leukocyte Antigen) disparity, and ...

Phase

0.0 miles

Learn More »

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

This is a prospective, multi-regional, observational cohort study with up to 3 years of follow up per patient. During the entire observational period (from the first patient first visit to the last patient last visit), vital status will be collected every 6 months on all patients, including those who complete ...

Phase N/A

0.0 miles

Learn More »

Open-Label Multicenter Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL

This is a multicenter, open-label, Phase 1/2 study that is being conducted in two parts. The Phase 1 part (closed to accrual as of January 25, 2016) is comprised of dose escalation and expansion parts to establish the MTD and/or the recommended Phase 2 dose (RP2D) when tazemetostat is given ...

Phase

0.0 miles

Learn More »

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order: STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with ...

Phase

0.0 miles

Learn More »

Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions

Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter in the treatment of de novo or restenotic lesions in the superficial femoral and/or popliteal arteries Cohort 2: To evaluate this patient population for treatment of in-stent restenotic ...

Phase N/A

0.0 miles

Learn More »

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

This study is designed as a prospective, randomized, multi-center trial. Data will be collected at enrollment, baseline, implant procedure, patient classification, 6 months and 12 months of follow-up. During the 6-month visit, the patient's response to CRT will be evaluated according to LVESV reduction. Patients with an LVESV reduction of ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD

Recruitment is closed to adults. Recruitment is open to adolescents 12-17 years old.

Phase

0.0 miles

Learn More »

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) will have limited stage disease, now called stage I-IIIB (IASLC). The outcome of limited disease SCLC is still poor, with a median survival of 16 to 24 months with current forms of treatment and only 15-25% ...

Phase

0.0 miles

Learn More »